Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Michal Hirsch Vexberg"'
Autor:
Katerina Shulman, Ilana Weiss, Matitiahu Berkovitch, Shai Ashkenazi, Moshe E Gatt, Osnat Luxenburg, Stephany Hiayev, Einat Shacham-Shmueli, Michal Hirsch Vexberg, Rami Hershkowitz, Einat Gorelik, Haim Mayan, Yehudit Steinmetz, Noa Berar Yanai, Orly Schlissel, Muhammad Azem, Neriya Gutgold, Milly Divinsky, Nirit Yarom, Alla Vishkautzan, Chezi Ganzel, Lidia Arcavi, Eli Marom, Biatrice Uziely, Shoshana Zevin, Hadar Meirow, Denize Ainbinder
Publikováno v:
BMJ Open, Vol 13, Iss 5 (2023)
Objectives US FDA and EMA allow facilitated regulatory pathways to expedite access to new treatments. Limited supportive data may result in major postapproval variations. In Israel, partly relying on Food and Drug Administration (FDA) and European Me
Externí odkaz:
https://doaj.org/article/5182d1f30202403fba42ed308f75acff
Autor:
Stephany Hiayev, Einat Shacham-Shmueli, Matitiahu Berkovitch, Ilana Weiss, Shai Ashkenazi, Michal Hirsch Vexberg, Rami Hershkowitz, Einat Gorelik, Haim Mayan, Yehudit Steinmetz, Noa Berar Yanai, Orly Schlissel, Muhammad Azem, Neriya Gutgold, Katerina Shulman, Milly Divinsky, Nirit Yarom, Alla Vishkautzan, Chezi Ganzel, Moshe E Gatt, Lidia Arcavi, Eli Marom, Biatrice Uziely, Shoshana Zevin, Hadar Meirow, Osnat Luxenburg, Denize Ainbinder
Publikováno v:
BMJ Open. 13:e067313
ObjectivesUS FDA and EMA allow facilitated regulatory pathways to expedite access to new treatments. Limited supportive data may result in major postapproval variations. In Israel, partly relying on Food and Drug Administration (FDA) and European Med
Publikováno v:
Diabetes. 67
Background: Dapagliflozin is a potential for combination therapy with metformin in T2DM. However, its cost-effectiveness relative to other alternatives in the Israeli healthcare setup remains unknown. Objective: To evaluate the cost-effectiveness of